β-defensin 29 Inhibitors
β-defensin 29 inhibitors are molecules that specifically target and inhibit the activity of β-defensin 29, a member of the defensin family of small, cysteine-rich cationic peptides. These peptides are known for their role in the immune system, where they exhibit a broad spectrum of activity, particularly in disrupting microbial membranes. Structurally, β-defensin 29, like other defensins, possesses a beta-sheet arrangement stabilized by disulfide bonds between cysteine residues, which is key to its stability and biological activity. The inhibition of β-defensin 29 is a complex chemical process, often involving small molecules or peptides that can bind to critical regions of β-defensin 29, preventing its interaction with cellular membranes or other molecular targets. Inhibitors might operate through competitive binding at active sites, altering the conformation of β-defensin 29, or via covalent modification of essential residues such as cysteines that form the disulfide bonds crucial for its structural integrity.
From a chemical perspective, designing β-defensin 29 inhibitors requires a thorough understanding of the peptide's structure-function relationships, particularly its surface charge, hydrophobicity, and spatial arrangement of functional groups. The charge distribution on β-defensin 29's surface, often characterized by regions of cationic and hydrophobic residues, provides key binding interfaces for inhibitors. Additionally, the disulfide bond network within β-defensin 29 presents a unique challenge in crafting inhibitors, as disrupting these bonds can lead to loss of the peptide's structural conformation. Advanced computational methods, such as molecular docking and dynamic simulations, are often employed to design and optimize inhibitors by predicting how various molecules interact with the peptide's surface.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor disrupting DNA repair. Olaparib indirectly inhibits β-defensin 29 by impeding the DNA damage response pathway, affecting the regulation of β-defensin 29 transcription under conditions of cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 29, as PI3K/AKT signaling is implicated in the regulation of β-defensin 29 transcription by modulating specific transcription factors. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 29 by blocking NFAT activation, a key regulator of β-defensin 29 transcription in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 29 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 29 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 29, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 29. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 29 by altering histone acetylation, influencing the accessibility of the β-defensin 29 gene for transcription. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 29, as HIF-1α enhances β-defensin 29 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $169.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 29, as TLR4 activation is known to upregulate β-defensin 29 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 29 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 29 through control of translation initiation. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
Notch signaling pathway inhibitor. RO4929097 indirectly suppresses β-defensin 29, as Notch signaling is linked to the regulation of β-defensin 29 expression by modulating specific transcription factors. | ||||||